Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models

Journal of Bone and Mineral Research

Volumn 26, Issue 10, 2011, Pages 2452-2462

  Rousseau, Julie ^a,b   Escriou, Virginie ^c,d   Lamoureux, François ^a,b   Brion, Régis ^a,b   Chesneau, Julie ^a,b   Battaglia, Séverine ^a,b   Amiaud, Jérome ^a,b   Scherman, Daniel ^c,d   Heymann, Dominique ^a,b   Rédini, Françoise ^a,b   Trichet, Valérie ^a,b  

^a Universite de Nantes   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d Centre National de la Recherche Scientifique   (France)

Author keywords

bitherapy; osteoclastogenesis inhibition; RANKL; siRNAs

Indexed keywords

IFOSFAMIDE; LIPOSOME; OSTEOCLAST DIFFERENTIATION FACTOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; PROTEIN EXPRESSION; RAT; SEQUENCE ANALYSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OSTEOLYSIS; OSTEOSARCOMA; RANK LIGAND; RATS; RNA, SMALL INTERFERING;

EID: 80053185152     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.455     Document Type: Article

References (60)

1. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS,. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. 1999; 91: 1051-8. (Pubitemid 29293044)
2. Goubin A, et al. Cancer incidence among children in France, 1990-1999. Pediatr Blood Cancer. 2004; 43: 749-57. (Pubitemid 39557711)
3. Kim HJ, Chalmers PN, Morris CD,. Pediatric osteogenic sarcoma. Curr Opin Pediatr. 2010; 22: 61-6.
4. Picci P,. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007; 2: 6.
5. Ward WG, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994; 12: 1849-58. (Pubitemid 24349387)
6. Chirgwin JM, Guise TA,. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Exp. 2000; 10: 159-78.
7. Heymann D, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005; 37: 74-86. (Pubitemid 40848420)
8. Ory B, et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005; 104: 2522-9. (Pubitemid 41691577)
9. Hoff AO, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23: 826-36. (Pubitemid 351768801)
10. Coleman RE,. Risks and benefits of bisphosphonates. Br J Cancer. 2008; 98: 1736-40. (Pubitemid 351748847)
11. Pozzi S, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009; 15: 5829-39.
12. Smith EJ, et al. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J Bone Miner Res. 2005; 20: 1731-41. (Pubitemid 41361874)
13. Rauch F, Cornibert S, Cheung M, Glorieux FH,. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007; 40: 821-7. (Pubitemid 46386546)
14. Walsh MC, Choi Y,. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003; 14: 251-63. (Pubitemid 36693145)
15. Grimaud E, et al. Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 2003; 163: 2021-31. (Pubitemid 37310032)
16. O'Brien CA,. Control of RANKL gene expression. Bone. 2010; 46: 911-9.
17. Oyajobi BO, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001; 61: 2572-8. (Pubitemid 32685841)
18. Jones DH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440: 692-6.
19. Heath DJ, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007; 67: 202-8. (Pubitemid 46142776)
20. Lamoureux F, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007; 67: 7308-18. (Pubitemid 47206560)
21. Lamoureux F, et al. Therapeutic efficacy of soluble receptor activator of nuclear factor κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther. 2008; 7: 3389-98.
22. Neville-Webbe HL, Coleman RE,. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 2010; 46: 1211-22.
23. Vallet S, Smith MR, Raje N,. Novel bone-targeted strategies in oncology. Clin Cancer Res. 2010; 16: 4084-93.
24. Fire A, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391: 806-11. (Pubitemid 28099681)
25. López-Fraga M, Martínez T, Jiménez A,. RNA interference technologies and therapeutics: from basic research to products. BioDrugs. 2009; 23: 305-32.
26. Khoury M, et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis Rheum. 2006; 54: 1867-77. (Pubitemid 43877936)
27. Khoury M, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008; 58: 2356-67.
28. Rousseau J, et al. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther. 2010; 17: 387-97.
29. Uesugi M, Koshino T, Mitsugi N, Hiruma T,. Predictive value of serum immunosuppressive acidic protein for lung metastasis after amputation of murine osteosarcoma of the lower limb. Cancer Lett. 2000; 155: 169-72. (Pubitemid 30259131)
30. Thiéry J, Perdereau B, Gongora G, Mazabraud A,. Un modèle expérimental d'ostéosarcome chez le rat. Sem Hôp Paris. 1982; 1686-9.
31. Cherrier B, et al. A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumour Biol. 2005; 26: 121-30. (Pubitemid 41379751)
32. Kutscher S, et al. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays. Gene Ther. 2010; DOI: 10.1038/gt.2010.90.
33. Reynolds A, et al. Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22: 326-330. (Pubitemid 38295766)
34. Hamdy NAT,. Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep. 2006; 8: 50-4. (Pubitemid 44659361)
35. Clark JCM, Dass CR, Choong PFM,. Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008; 13: 609-27.
36. Terpos E, et al. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther 2009; 9: 465-79.
37. Iqbal J, Sun L, Zaidi M,. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep. 2010; 8: 163-7.
38. Unni KK,. Osteosarcoma of bone. J Orthop Sci. 1998; 3: 287-94. (Pubitemid 28455224)
39. Arndt CA, Crist WM,. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999; 341: 342-52.
40. Bullought PE., Orthopaedic pathology. New York: Elsevier; 2010.
41. Bumcrot D, Manoharan M, Koteliansky V, Sah WY,. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006; 2: 711-9. (Pubitemid 44764213)
42. Endo-Munoz L, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010; 70: 7063-72.
43. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG,. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003; 5: 834-9. (Pubitemid 37087172)
44. Marques JT, Williams BRG,. Activation of the mammalian immune system by siRNAs. Nat Biotechnol, 2005; 3: 1399-1405. (Pubitemid 41679392)
45. Pan Y, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452: 591-7. (Pubitemid 351483358)
46. Ma Z, et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005; 330: 755-9. (Pubitemid 40462151)
47. Robbins M, Judge A, MacLachlan I,. siRNA and innate immunity. Oligonucleotides. 2009; 19: 89-102.
48. Meyers PA, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2010; DOI: 10.1002/cncr.25744.
49. Rosen G, Nirenberg A,. Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res. 1985; 201: 39-51.
50. Nanes MS,. Preventing metastases to bone: denosumab or bisphosphonates ? J Bone Miner Res. 2010; 25: 437-9.
51. Rosen LS, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004; 100: 36-43. (Pubitemid 37553537)
52. Papapetrou PD,. Bisphosphonate-associated adverse events. Hormones (Athens). 2009; 8: 96-110.
53. Weide R, et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs ibandronate: a retrospective medical records review. J Cancer Res Ther. 2010; 6: 31-5.
54. Body J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res. 2010; 25: 440-6.
55. Stopeck AT, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-9.
56. Miller RE, et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008; 7: 2160-9.
57. Canon J, et al. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone. 2010; 46: 1613-9.
58. Fan J, Zhou J, Yu G, Lu D,. Glucose transporter protein 1-targeted RNA interference inhibits growth and invasion of the osteosarcoma cell line MG63 in vitro. Cancer Biother Radiopharm. 2010; 25: 521-7.
59. Wang R, et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med. 2007; 13: 567-75. (Pubitemid 350228717)
60. Zhao Y, et al. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun. 2009; 390: 642-7.